CN111491920B - 毒蕈碱性乙酰胆碱受体m4的拮抗剂 - Google Patents

毒蕈碱性乙酰胆碱受体m4的拮抗剂 Download PDF

Info

Publication number
CN111491920B
CN111491920B CN201880081828.0A CN201880081828A CN111491920B CN 111491920 B CN111491920 B CN 111491920B CN 201880081828 A CN201880081828 A CN 201880081828A CN 111491920 B CN111491920 B CN 111491920B
Authority
CN
China
Prior art keywords
hexahydro
cyclopenta
pyridazin
pyrrol
amine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201880081828.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN111491920A (zh
Inventor
C.W.林斯利
P.J.孔
D.W.恩格尔斯
J.L.恩格尔斯
K.J.滕普尔
A.M.本德
L.A.贝克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vanderbilt University
Original Assignee
Vanderbilt University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vanderbilt University filed Critical Vanderbilt University
Priority to CN202410064006.9A priority Critical patent/CN118063442A/zh
Publication of CN111491920A publication Critical patent/CN111491920A/zh
Application granted granted Critical
Publication of CN111491920B publication Critical patent/CN111491920B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Indole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201880081828.0A 2017-10-20 2018-10-20 毒蕈碱性乙酰胆碱受体m4的拮抗剂 Active CN111491920B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202410064006.9A CN118063442A (zh) 2017-10-20 2018-10-20 毒蕈碱性乙酰胆碱受体m4的拮抗剂

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762574912P 2017-10-20 2017-10-20
US62/574912 2017-10-20
PCT/US2018/056803 WO2019079783A1 (en) 2017-10-20 2018-10-20 ANTAGONISTS OF THE MUSCARINIC RECEPTOR OF ACETYLCHOLINE M4

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202410064006.9A Division CN118063442A (zh) 2017-10-20 2018-10-20 毒蕈碱性乙酰胆碱受体m4的拮抗剂

Publications (2)

Publication Number Publication Date
CN111491920A CN111491920A (zh) 2020-08-04
CN111491920B true CN111491920B (zh) 2024-01-30

Family

ID=66173904

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201880081828.0A Active CN111491920B (zh) 2017-10-20 2018-10-20 毒蕈碱性乙酰胆碱受体m4的拮抗剂
CN202410064006.9A Pending CN118063442A (zh) 2017-10-20 2018-10-20 毒蕈碱性乙酰胆碱受体m4的拮抗剂

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202410064006.9A Pending CN118063442A (zh) 2017-10-20 2018-10-20 毒蕈碱性乙酰胆碱受体m4的拮抗剂

Country Status (9)

Country Link
US (3) US11299481B2 (enExample)
EP (1) EP3697759A4 (enExample)
JP (1) JP7270989B2 (enExample)
KR (2) KR20250037575A (enExample)
CN (2) CN111491920B (enExample)
AU (2) AU2018351651B2 (enExample)
CA (1) CA3079617A1 (enExample)
IL (2) IL310346A (enExample)
WO (1) WO2019079783A1 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA202092442A3 (ru) 2016-06-07 2021-08-31 Джакобио Фармасьютикалс Ко., Лтд. Новые гетероциклические производные, применимые в качестве ингибиторов shp2
KR102317480B1 (ko) 2017-03-23 2021-10-25 자코바이오 파마슈티칼스 컴퍼니 리미티드 Shp2 억제제로서 유용한 신규한 헤테로환형 유도체
JP7065951B2 (ja) 2017-09-22 2022-05-12 ジュビラント エピパッド エルエルシー Ｐａｄ阻害剤としての複素環式化合物
WO2019077631A1 (en) 2017-10-18 2019-04-25 Jubilant Biosys Limited IMIDAZO-PYRIDINE COMPOUNDS FOR USE AS PAD INHIBITORS
CA3079617A1 (en) 2017-10-20 2019-04-25 Vanderbilt University Antagonists of the muscarinic acetylcholine receptor m4
WO2019089676A1 (en) 2017-10-31 2019-05-09 Vanderbilt University Antagonists of the muscarinic acetylcholine receptor m4
EP3707135A1 (en) 2017-11-06 2020-09-16 Jubilant Prodel LLC Pyrimidine derivatives as inhibitors of pd1/pd-l1 activation
IL274762B2 (en) 2017-11-24 2023-10-01 Jubilant Episcribe Llc Novel heterocyclic compounds as prmt5 inhibitors
US11667651B2 (en) 2017-12-22 2023-06-06 Hibercell, Inc. Aminopyridine derivatives as phosphatidylinositol phosphate kinase inhibitors
IL276411B2 (en) * 2018-02-02 2024-04-01 Univ Vanderbilt M4 muscarinic acetylcholine receptor antagonists
WO2019175897A1 (en) 2018-03-13 2019-09-19 Jubilant Biosys Limited Bicyclic compounds as inhibitors of pd1/pd-l1 interaction/activation
WO2020063760A1 (en) 2018-09-26 2020-04-02 Jacobio Pharmaceuticals Co., Ltd. Novel heterocyclic derivatives useful as shp2 inhibitors
TW202112767A (zh) 2019-06-17 2021-04-01 美商佩特拉製藥公司 作為磷脂酸肌醇磷酸激酶抑制劑之胺基吡啶衍生物
US12319701B2 (en) 2019-10-04 2025-06-03 Vanderbilt University Antagonists of the muscarinic acetylcholine receptor M4
US20230122344A1 (en) * 2019-12-10 2023-04-20 Vanderbilt University Antagonists of the muscarinic acetylcholine receptor m4
JP2023506741A (ja) * 2019-12-10 2023-02-20 ヴァンダービルト ユニバーシティー ムスカリン性アセチルコリン受容体ｍ４のアンタゴニスト
CN115551847A (zh) * 2020-02-28 2022-12-30 雷密克斯医疗公司 用于调节核酸剪接的哒嗪衍生物
JP2023522959A (ja) * 2020-04-24 2023-06-01 ヴァンダービルト ユニヴァーシティ ムスカリンアセチルコリン受容体ｍ４のアンタゴニストとしての縮合置換ヒドロピロール
AU2021261002A1 (en) * 2020-04-24 2022-11-17 Vanderbilt University Condensed substituted hydropyrroles as antagonists of the muscarinic acetylcholine receptor m4
US20230322799A1 (en) * 2020-08-13 2023-10-12 Vanderbilt University Antagonists of the muscarinic acetylcholine receptor m4
JP2023549534A (ja) * 2020-11-18 2023-11-27 ヴァンダービルト ユニヴァーシティ ムスカリン性アセチルコリン受容体ｍ４のアンタゴニスト
CN116669737A (zh) * 2020-12-22 2023-08-29 范德堡大学 毒蕈碱型乙酰胆碱受体m4的拮抗剂
KR20230124608A (ko) * 2020-12-22 2023-08-25 반더빌트유니버시티 무스카린성 아세틸콜린 수용체 m4의 길항제
CA3214469A1 (en) * 2021-04-01 2022-10-06 Ono Pharmaceutical Co., Ltd. Abhd6 antagonist
US20240174655A1 (en) * 2021-04-02 2024-05-30 Vanderbilt University Indazole derivatives as antagonists of the muscarinic acetylcholine receptor m4
WO2022216655A1 (en) * 2021-04-05 2022-10-13 Vanderbilt University N-(6-((octahydrocyclopenta[c]pyrrol-5-yi)amino)pyridazin-3-yl)phenyl)carboxamide and (6- ((octahydrocyclopenta[c]pyrrol-5-yl)amino)pyridazin-3-yl)benzamide derivatives as machr m4 antagonists for the treatment of neurodegenerative disorders
JP2024532729A (ja) * 2021-08-09 2024-09-10 シロナックス リミテッド． フェロトーシス調節物質、その調製及び使用
US20250101041A1 (en) * 2022-01-19 2025-03-27 Vanderbilt University Positive allosteric modulators of the muscarinic acetylcholine receptor m4

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5726172A (en) * 1996-01-16 1998-03-10 Merck & Co., Inc. Tocolytic oxytocin receptor antagonists
WO2004006846A2 (en) * 2002-07-15 2004-01-22 Exelixis, Inc. Receptor-type kinase modulators and methods of use
WO2005030140A2 (en) * 2003-09-26 2005-04-07 Exelixis, Inc. C-met modulators and methods of use
WO2007138431A2 (en) * 2006-05-30 2007-12-06 Pfizer Products Inc. Azabicyclic ether histamine-3 antagonists
WO2008065500A2 (en) * 2006-11-30 2008-06-05 Pfizer Products Inc. Heteroaryl amides as type i glycine transport inhibitors
CN102686581A (zh) * 2009-12-21 2012-09-19 张强 新的喹唑啉衍生物
CN103102352A (zh) * 2011-11-15 2013-05-15 山东亨利医药科技有限责任公司 酪氨酸激酶抑制剂吲哚满酮衍生物
WO2015119899A1 (en) * 2014-02-06 2015-08-13 Merck Sharp & Dohme Corp. Antidiabetic compounds

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040044029A1 (en) 2002-08-14 2004-03-04 Dart Michael J. Azabicyclic compounds are central nervous system active agents
ATE386738T1 (de) 2002-12-23 2008-03-15 Ranbaxy Lab Ltd Flavaxat-derivate als muscarin-rezeptor antagonisten
US7517905B2 (en) 2003-04-09 2009-04-14 Ranbaxy Laboratories Limited Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists
DE102004039789A1 (de) 2004-08-16 2006-03-02 Sanofi-Aventis Deutschland Gmbh Arylsubstituierte polycyclische Amine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US20090176856A1 (en) 2004-09-27 2009-07-09 Anita Mehta Muscarinic receptor antagonists
WO2006035280A1 (en) 2004-09-27 2006-04-06 Ranbaxy Laboratories Limited 3,4-dihydroisoquinoline compounds as muscrinic receptor antagonists for the treatment of respiratory, urinary and gastrointestinal diseases
GB0510204D0 (en) 2005-05-19 2005-06-22 Chroma Therapeutics Ltd Enzyme inhibitors
US20080255188A1 (en) 2005-07-11 2008-10-16 Naresh Kumar Muscarinic Receptor Antagonists
GB0521508D0 (en) 2005-10-21 2005-11-30 Novartis Ag Organic compounds
CA2672373C (en) 2006-12-19 2011-08-30 Pfizer Products Inc. Nicotinamide derivatives as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases
CN101230058A (zh) 2007-01-23 2008-07-30 上海恒瑞医药有限公司 双环氮杂烷类衍生物、其制备方法及其在医药上的用途
JP2012107001A (ja) * 2010-10-22 2012-06-07 Shionogi & Co Ltd インドールアミド化合物を含有する医薬
EP2970200A1 (en) 2013-03-13 2016-01-20 Abbvie Inc. Pyridine cdk9 kinase inhibitors
WO2015150995A1 (en) 2014-04-04 2015-10-08 Pfizer Inc. Bicyclic-fused heteroaryl or aryl compounds and their use as irak4 inhibitors
HUE054784T2 (hu) 2014-05-23 2021-09-28 Hoffmann La Roche 5-klór-2-difluor-metoxifenil-pirazolopirimidin vegyületek, amelyek JAK-gátlók
JO3579B1 (ar) 2014-09-26 2020-07-05 Luc Therapeutics Inc مُعدِلات تفاغرية سالبة لمستقبل nr2b من المركب n-ألكيل أريل-5-أوكسي أريل-ثامن هيدرو-خماسي الحلقة [c] بيرول
EP3371164B1 (en) 2015-11-06 2022-03-16 Neurocrine Biosciences, Inc. N-[2-(1-benzylpiperidin-4-yl)ethyl]-4-(pyrazin-2-yl)-piperazine-1-carboxamide derivatives and related compounds as muscarinic receptor 4 (m4) antagonists for treating neurological diseases
JP2019504901A (ja) 2016-02-16 2019-02-21 ヴァンダービルト ユニバーシティー ムスカリン性アセチルコリン受容体ｍ１のポジティブアロステリックモジュレーター
US20170355708A1 (en) 2016-06-09 2017-12-14 Cadent Therapeutics, Inc. Potassium channel modulators
WO2018093694A1 (en) * 2016-11-17 2018-05-24 Merck Sharp & Dohme Corp. Diamino-alkylamino-linked arylsulfonamide compounds with selective activity in voltage-gated sodium channels
US11225484B2 (en) 2017-08-08 2022-01-18 Vanderbilt University Substituted octahydropyrrolo[3,4-b]pyrroles as antagonists of the muscarinic acetylcholine receptor M4
AU2018352828A1 (en) 2017-10-17 2020-04-23 Vanderbilt University Antagonists of the muscarinic acetylcholine receptor M4
CA3079617A1 (en) * 2017-10-20 2019-04-25 Vanderbilt University Antagonists of the muscarinic acetylcholine receptor m4
WO2019089676A1 (en) * 2017-10-31 2019-05-09 Vanderbilt University Antagonists of the muscarinic acetylcholine receptor m4
US11325896B2 (en) 2017-12-20 2022-05-10 Vanderbilt University Antagonists of the muscarinic acetylcholine receptor M4
JP2023506741A (ja) * 2019-12-10 2023-02-20 ヴァンダービルト ユニバーシティー ムスカリン性アセチルコリン受容体ｍ４のアンタゴニスト
US20230122344A1 (en) * 2019-12-10 2023-04-20 Vanderbilt University Antagonists of the muscarinic acetylcholine receptor m4
AU2021261002A1 (en) * 2020-04-24 2022-11-17 Vanderbilt University Condensed substituted hydropyrroles as antagonists of the muscarinic acetylcholine receptor m4
JP2023522959A (ja) * 2020-04-24 2023-06-01 ヴァンダービルト ユニヴァーシティ ムスカリンアセチルコリン受容体ｍ４のアンタゴニストとしての縮合置換ヒドロピロール
KR20230124608A (ko) * 2020-12-22 2023-08-25 반더빌트유니버시티 무스카린성 아세틸콜린 수용체 m4의 길항제
US20240174655A1 (en) * 2021-04-02 2024-05-30 Vanderbilt University Indazole derivatives as antagonists of the muscarinic acetylcholine receptor m4
WO2022216655A1 (en) * 2021-04-05 2022-10-13 Vanderbilt University N-(6-((octahydrocyclopenta[c]pyrrol-5-yi)amino)pyridazin-3-yl)phenyl)carboxamide and (6- ((octahydrocyclopenta[c]pyrrol-5-yl)amino)pyridazin-3-yl)benzamide derivatives as machr m4 antagonists for the treatment of neurodegenerative disorders
US20240287050A1 (en) * 2021-06-11 2024-08-29 Vanderbilt University (4-(6-((2-octahydrocyclopenta[c]pyrrol-5-yl)amino)pyridazin-3-yl)phenyl)(imino)(methyl)-lambda6- sulfanone derivatives and similar compounds as muscarinic acetylcholine receptor m4 antagonists for the treatment of neurodegenerative disorders

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5726172A (en) * 1996-01-16 1998-03-10 Merck & Co., Inc. Tocolytic oxytocin receptor antagonists
WO2004006846A2 (en) * 2002-07-15 2004-01-22 Exelixis, Inc. Receptor-type kinase modulators and methods of use
WO2005030140A2 (en) * 2003-09-26 2005-04-07 Exelixis, Inc. C-met modulators and methods of use
WO2007138431A2 (en) * 2006-05-30 2007-12-06 Pfizer Products Inc. Azabicyclic ether histamine-3 antagonists
WO2008065500A2 (en) * 2006-11-30 2008-06-05 Pfizer Products Inc. Heteroaryl amides as type i glycine transport inhibitors
CN102686581A (zh) * 2009-12-21 2012-09-19 张强 新的喹唑啉衍生物
CN103102352A (zh) * 2011-11-15 2013-05-15 山东亨利医药科技有限责任公司 酪氨酸激酶抑制剂吲哚满酮衍生物
WO2015119899A1 (en) * 2014-02-06 2015-08-13 Merck Sharp & Dohme Corp. Antidiabetic compounds

Also Published As

Publication number Publication date
IL310346A (en) 2024-03-01
IL273924A (en) 2020-05-31
US20210188820A1 (en) 2021-06-24
US11299481B2 (en) 2022-04-12
AU2018351651B2 (en) 2023-01-05
US20220213069A1 (en) 2022-07-07
CN111491920A (zh) 2020-08-04
EP3697759A1 (en) 2020-08-26
EP3697759A4 (en) 2021-05-12
KR102776114B1 (ko) 2025-03-07
AU2018351651A1 (en) 2020-06-04
IL273924B1 (en) 2024-03-01
CA3079617A1 (en) 2019-04-25
WO2019079783A1 (en) 2019-04-25
AU2023202086A1 (en) 2023-05-04
IL273924B2 (en) 2024-07-01
KR20250037575A (ko) 2025-03-17
KR20200074164A (ko) 2020-06-24
US11820757B2 (en) 2023-11-21
US20240116902A1 (en) 2024-04-11
AU2023202086B2 (en) 2025-04-03
JP2021500345A (ja) 2021-01-07
JP7270989B2 (ja) 2023-05-11
CN118063442A (zh) 2024-05-24

Similar Documents

Publication Publication Date Title
CN111491920B (zh) 毒蕈碱性乙酰胆碱受体m4的拮抗剂
CN111788182B (zh) 毒蕈碱性乙酰胆碱受体m4的拮抗剂
US11225484B2 (en) Substituted octahydropyrrolo[3,4-b]pyrroles as antagonists of the muscarinic acetylcholine receptor M4
US20230122344A1 (en) Antagonists of the muscarinic acetylcholine receptor m4
US20230183219A1 (en) Condensed substituted hydropyrroles as antagonists of the muscarinic acetylcholine receptor m4
US20200339547A1 (en) Antagonists of the muscarinic acetylcholine receptor m4
US20230183218A1 (en) Condensed substituted hydropyrroles as antagonists of the muscarinic acetylcholine receptor m4
EP4037677B1 (en) Antagonists of the muscarinic acetylcholine receptor m4
US20230150986A1 (en) Antagonists of the muscarinic acetylcholine receptor m4
US20240010640A1 (en) Antagonists of the muscarinic acetylcholine receptor m4
US20230322799A1 (en) Antagonists of the muscarinic acetylcholine receptor m4

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant